CN101406576A - Chinese medicine for treating diabetes and preparation method - Google Patents
Chinese medicine for treating diabetes and preparation method Download PDFInfo
- Publication number
- CN101406576A CN101406576A CNA2008101624011A CN200810162401A CN101406576A CN 101406576 A CN101406576 A CN 101406576A CN A2008101624011 A CNA2008101624011 A CN A2008101624011A CN 200810162401 A CN200810162401 A CN 200810162401A CN 101406576 A CN101406576 A CN 101406576A
- Authority
- CN
- China
- Prior art keywords
- rhizoma coptidis
- extractum
- diabetes
- chinese medicine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a traditional Chinese medicine for treating diabetes and a preparation method thereof. The traditional Chinese medicine is prepared from the following materials in weight percentage: 20 to 50 percent of rhizoma coptidis, 20 to 50 percent of red ginseng, 10 to 20 percent of Alisma orientale and 10 to 20 percent of radix puerariae. The rhizoma coptidis is refluxed by alcohol; the red ginseng, the Alisma orientale and the radix puerariae are extracted by adding water; and extracts are dried and tabletted to obtain the traditional Chinese medicine. The traditional Chinese medicine has functions of treating the diabetes and complicating diseases of the diabetes by reducing blood sugar and blood fat, reducing cataract, improving the weak constitution of diabetes patients and so on.
Description
Technical field
The present invention relates to field of traditional Chinese medicine pharmacy, especially, relate to a kind of Chinese medicine and preparation method for the treatment of diabetes.
Background technology
Diabetes are a kind of commonly encountered diseases, frequently-occurring disease.Diabetic duration is long, does not still have the radical cure method at present.Because the death toll that diabetic complication causes has been to be listed as the 3rd after cardiovascular and cerebrovascular disease, tumor in developed country, has caused the great attention of countries in the world, numerous and confused pathogenesis to diabetes, medical treatment etc. are studied.
At present, the blood sugar lowering market of China accounts for 73.68% of whole market share based on Western medicine; Chinese patent medicine is auxilliary, accounts for 24.7%.What account for blood sugar lowering series products absolute advantages share mainly is the chemical classes antidiabetic drug, though hypoglycemic effect is rapid, but act on single, increase the islets of langerhans burden, and side effect such as take medicine for a long time hypoglycemia, part and the general reaction that cause, drug resistance, insulin resistant, lesions of liver and kidney allow all diabetics fully feel misery.
The Chinese medicine extensive knowledge and profound scholarship, each big school of the traditional Chinese medical science, all kinds of medical book, many in old well-known doctor the understanding of a certain disease is also had repugnancy, the prescription that they determine often has their own characteristics each, and is different.The a lot of effects of the Chinese patent medicine of having developed are slow, blood sugar reducing function is obvious inadequately and unstable, effectively many complication of control of diabetes.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, a kind of Chinese medicine and preparation method for the treatment of diabetes is provided, this Chinese medicine has blood sugar lowering, blood fat, reduces cataractous generation, improves the function of treatment diabetes such as the weakly body constitution of diabetes patient and complication thereof.
The objective of the invention is to be achieved through the following technical solutions: a kind of Chinese medicine for the treatment of diabetes, it is that 20～50% Rhizoma Coptidis, 20～50% Radix Ginseng Rubra, 10～20% Rhizoma Alismatis and 10～20% Radix Puerariae are made by percentage by weight.
The preparation method of Chinese medicine of the described treatment diabetes of a kind of claim 1 may further comprise the steps:
(1) takes by weighing material according to mass percent Rhizoma Coptidis 20～50%, Radix Ginseng Rubra 20～50%, Rhizoma Alismatis 10～20%, Radix Puerariae 10～20%.
(2) get Rhizoma Coptidis, add percent by volume and be 60～80% medicinal alcohol and reflux 1～3 time, each ethanol consumption is 7～9 times of medical material amount, each 0.5～1.5 hour; Collect alcohol reflux liquid, filter decompression recycling ethanol; Concentrated solution adds hydrochloric acid and transfers pH value to 2.0～3.0, standing over night, sucking filtration; Precipitate is added the hot water dissolving, filter, filtrate concentrates, the cooling standing over night, and sucking filtration, precipitate obtains Rhizoma Coptidis extract at 50～60 ℃ of following oven drying at low temperatures, and is standby.
(3) get Radix Ginseng Rubra, Rhizoma Alismatis, Radix Puerariae, extracting in water 1～3 time, each 0.5～1.5 hour, each 9～11 times of water gagings, merge each time water extract, filter, be concentrated into relative density 1.0～1.2, add ethanol and reach 60～80% to containing the alcohol amount, standing over night is filtered decompression filtrate recycling ethanol, medicine is concentrated into the concentrated solution of relative density 1.20～1.40 night, and is standby;
(4) get above-mentioned Rhizoma Coptidis extract and mix, get extractum with concentrated solution.
(5) get extractum, vacuum drying, dry thing is pulverized, sieve, the powder that gets dry extract adds mass percent and is lactose, 5%～7% sodium carboxymethyl cellulose, 10%～14% microcrystalline Cellulose and 0.6%～0.8% the medicinal magnesium stearate of dried cream powder quality 4%～6%, tabletting makes tablet.Or get extractum, and adding quality is the Icing Sugar of 1～2 times of amount of extractum quality and the mixture of dextrin, the weight ratio of Icing Sugar and dextrin is 1: 0.5～1 in the mixture, adopts the boiling granulating method to make granule, gets granule.Or get extractum, and vacuum drying, dry thing is pulverized, sieves, the powder that gets dry extract, adding percentage by weight is the starch mixing of dried cream powder quality 20%～25%, filled capsules makes capsule.
The present invention has following technique effect: the Chinese medicine of treatment diabetes of the present invention can reduce blood glucose, blood fat, the cataractous incidence rate of diabetics, improves the weakly body constitution of diabetes patient.
The specific embodiment
Chinese medicine diabetes (the ancient diabetes that claims) are with a long history, accumulated rich experience.According to statistics, the prescription for the treatment of diabetes at all times has more than 500, relate to Chinese medicine hundreds of.We utilize the modern pharmacology method, rely on diabetes and the chronic complicating diseases herbal medicine efficacy thereof that us set up to estimate platform, develop stable curative effect and treat diabetes Chinese medicine reliably, and the applicant is with its called after: the Rhizoma Coptidis metformin.
The present invention treats the Chinese medicine of diabetes, and the raw medicinal material and the mass percent thereof of its active ingredient are as follows: Rhizoma Coptidis 20～50%, Radix Ginseng Rubra 20～50%, Rhizoma Alismatis 10～20%, Radix Puerariae 10～20%.
The present invention treats the Chinese medicine of diabetes, can make the multiple dosage form on the pharmaceutics, as granule, and capsule or tablet.
The preparation method of Chinese medicine that the present invention treats diabetes may further comprise the steps:
1) takes by weighing material according to mass percent Rhizoma Coptidis 20～50%, Radix Ginseng Rubra 20～50%, Rhizoma Alismatis 10～20%, Radix Puerariae 10～20%.
2) get Rhizoma Coptidis, add percent by volume and be 60～80% medicinal alcohol and reflux 1～3 time, each ethanol consumption is 7～9 times of medical material amount, each 0.5～1.5 hour.Collect alcohol reflux liquid, filter decompression recycling ethanol.Concentrated solution adds hydrochloric acid and transfers pH value to 2.0～3.0, standing over night, sucking filtration.Precipitate is added the hot water dissolving, filter, filtrate concentrates, the cooling standing over night, and sucking filtration, precipitate is at 50～60 ℃ of following oven drying at low temperatures.Obtain Rhizoma Coptidis extract, standby.
3) get Radix Ginseng Rubra, Rhizoma Alismatis, Radix Puerariae, extracting in water 1～3 time, each 0.5～1.5 hour, each 9～11 times of water gagings, merge each time water extract, filter, be concentrated into relative density 1.0～1.2, add ethanol and reach 60 ~ 80% to containing the alcohol amount, standing over night is filtered decompression filtrate recycling ethanol, medicine is concentrated into the concentrated solution of relative density 1.20 ~ 1.40 night, and is standby;
4) get above-mentioned Rhizoma Coptidis extract and mix, get extractum with concentrated solution.
5) get extractum, (50～70 ℃ of vacuum dryings, 600mm～800Hg), dry thing is pulverized, sieve, the powder that gets dry extract adds mass percent and is lactose, 5%～7% sodium carboxymethyl cellulose, 10%～14% microcrystalline Cellulose and 0.6%～0.8% the medicinal magnesium stearate of dried cream powder quality 4%～6%, tabletting makes tablet.Or get extractum, and adding quality is the Icing Sugar of 1～2 times of amount of extractum quality and the mixture of dextrin, the weight ratio of Icing Sugar and dextrin is 1: 0.5～1 in the mixture, adopts the boiling granulating method to make granule, gets granule.Or get extractum, and vacuum drying (50～70 ℃, 600～800mmHg), dry thing is pulverized, sieves, the powder that gets dry extract, adding percentage by weight is the starch mixing of dried cream powder quality 20%～25%, filled capsules makes capsule.
The invention will be further described below by embodiment and toxicology and pharmacology experimental result.
Embodiment one
Get Rhizoma Coptidis 400g, add 70% medicinal alcohol and reflux three times, each ethanol consumption is 8 times of medical material amount, each 1 hour.Collect alcohol reflux liquid, filter decompression recycling ethanol.Concentrated solution adds hydrochloric acid and transfers pH value to 2.0～3.0, standing over night, sucking filtration.Precipitate is added the hot water dissolving, filter, filtrate concentrates, the cooling standing over night, and sucking filtration, precipitate low temperature (50～60 ℃) oven dry obtains Rhizoma Coptidis extract.Get Radix Ginseng Rubra 400g, Rhizoma Alismatis 200g, Radix Puerariae 200g, extracting in water twice, each one hour, each 10 times of amounts, merge 2 times the water extract, filter, be concentrated into relative density 1.15, add ethanol and reach 70% to containing the alcohol amount, standing over night, filter, decompression filtrate recycling ethanol, medicine are concentrated into relative density 1.30 night.Get above-mentioned Rhizoma Coptidis extract and mix, get extractum with concentrated solution.The extractum vacuum drying (60 ℃, 700mmHg), dry thing is pulverized, and sieves, and adds 5% lactose, 6% sodium carboxymethyl cellulose, 12% microcrystalline Cellulose and 0.7% medicinal magnesium stearate, and tabletting promptly gets tablet of the present invention.
Embodiment two
Get Rhizoma Coptidis 240g, add 70% medicinal alcohol and reflux three times, each ethanol consumption is 8 times of medical material amount, each 1 hour.Collect alcohol reflux liquid, filter decompression recycling ethanol.Concentrated solution adds hydrochloric acid and transfers pH value to 2.0～3.0, standing over night, sucking filtration.Precipitate is added the hot water dissolving, filter, filtrate concentrates, the cooling standing over night, and sucking filtration, precipitate low temperature (50～60 ℃) oven dry obtains Rhizoma Coptidis extract.Get Radix Ginseng Rubra 600g, Rhizoma Alismatis 120g, Radix Puerariae 240g, extracting in water twice, each one hour, each 10 times of amounts, merge 2 times the water extract, filter, be concentrated into relative density 1.15, add ethanol and reach 70% to containing the alcohol amount, standing over night, filter, decompression filtrate recycling ethanol, medicine are concentrated into relative density 1.30 night.Get above-mentioned Rhizoma Coptidis extract and mix, get extractum with concentrated solution.Get above-mentioned extractum, the Icing Sugar and the dextrin that add 1.5 times of amounts adopt the boiling granulating method to make granule, promptly get granule of the present invention.
Embodiment three
Get Rhizoma Coptidis 600g, add 70% medicinal alcohol and reflux three times, each ethanol consumption is 8 times of medical material amount, each 1 hour.Collect alcohol reflux liquid, filter decompression recycling ethanol.Concentrated solution adds hydrochloric acid and transfers pH value to 2.0～3.0, standing over night, sucking filtration.Precipitate is added the hot water dissolving, filter, filtrate concentrates, the cooling standing over night, and sucking filtration, precipitate low temperature (50～60 ℃) oven dry obtains Rhizoma Coptidis extract.Get Radix Ginseng Rubra 240g, Rhizoma Alismatis 240g, Radix Puerariae 120g, extracting in water twice, each one hour, each 10 times of amounts, merge 2 times the water extract, filter, be concentrated into relative density 1.15, add ethanol and reach 70% to containing the alcohol amount, standing over night, filter, decompression filtrate recycling ethanol, medicine are concentrated into relative density 1.30 night.Get above-mentioned Rhizoma Coptidis extract and mix, get extractum with concentrated solution.With the extractum vacuum drying (60 ℃, 700mmHg), dry thing is pulverized, and sieves, adding percentage by weight is the starch mixing of 22% dried cream powder amount, filled capsules promptly gets capsule of the present invention.
The present invention is to provide a kind of Chinese medicine for the treatment of diabetes, the applicant is with its called after Rhizoma Coptidis metformin.For proving its therapeutic effect and safety, the tablet that the method that the inventor uses to be provided in the foregoing description prepares has carried out toxicity and pharmacodynamics test, and result of study is as follows:
One, animal toxicity test data:
The Rhizoma Coptidis metformin is drafted the clinical dosage and the course of treatment: one day three times, and each three, one month course of treatment.
The Rhizoma Coptidis metformin is once irritated stomach with 80g crude drug/Kg body weight and is given mice and do not have overt toxicity reaction, no dead mouses in two weeks, in dissecting inspection do not see yet any unusually.The maximal non-toxic dosage that records tablet its mouse oral of the present invention administration is 80g crude drug/Kg, 160 times of the oral dose on the one that is equivalent to be grown up.
The Rhizoma Coptidis metformin (calculates to become body weight for humans 60kg with 25g crude drug/kg, 12.5g crude drug/kg, 6.25g crude drug/kg, being equivalent to the people and intending with clinical dosage 50,25,12.5 times) three dosage are to the continuous gastric infusion of rat 6 months, matched group is given the equal-volume normal saline, and the body weight of rat, active situation, food-intake, appearance sign etc. are all had no adverse effects; Hematology, blood parameters testing result show, index no significant differences such as the hemogram of administration group and matched group, total serum protein, albumin, creatinine, blood urea nitrogen, blood glucose, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, alkali phosphatase, cholesterol and total bilirubin; Live and to cut open between inspection each main organs coefficient administration group of back and the matched group also no significant difference extremely; Pathological examination results, each organizes the main organs of rat does not all have obvious pathological changes generation.Illustrate that to take the clinical dosage and the course of treatment be safe to the Rhizoma Coptidis metformin by drafting.
Two, function cures mainly relevant Pharmacodynamic test of active extract:
(1) the Rhizoma Coptidis metformin is to the influence of normal mouse blood sugar
ICR Mus 50, ♀, ♂ dual-purpose are divided into 5 groups at random: matched group is irritated stomach equal-volume water, and positive group gives diabetes pill 2.5g/kg, and other three groups give the Rhizoma Coptidis metformin shown in the table 1 large, medium and small three dosage respectively.Irritate stomach every day 1 time, successive administration 3 days, the 30min eye socket is got blood after the administration in the 3rd day, and separation of serum is surveyed blood glucose with the GOD-POP method, the results are shown in Table 1.
Table 1 Rhizoma Coptidis metformin is to the influence of normal mouse blood sugar (X ± S)
Compare * P＜0.05 with matched group; * * P＜0.001
Last table result shows that the Rhizoma Coptidis metformin does not have hypoglycemic activity to normal mouse.
(2) the Rhizoma Coptidis metformin is to the influence of normal mouse glucose tolerance
60 of mices, ♀, ♂ half and half are divided into 6 groups at random: matched group, model group are fed equal-volume normal saline water; Positive group diabetes pill 2.5g/kg, the large, medium and small dosage group of Rhizoma Coptidis metformin is by dosed administration shown in the table.Every day, gastric infusion was 1 time, for three days on end, fasting 4h before the last administration, 30min after the administration, except that matched group, lumbar injection glucose solution 2g/kg, before giving sugar 0min, get eye socket blood survey blood glucose (GOD-POP method) for sugar back 60min, 120min, the results are shown in Table 2.
Table 2 Rhizoma Coptidis metformin is to the influence of normal mouse glucose tolerance (X ± S)
Compare with model group: * P＜0.05; * P＜0.01; * * P＜0.001.
Table 2 is the result show, diabetes pill and Rhizoma Coptidis metformin high dose group are obvious to improving the effect of mice carbohydrate tolerance; In the Rhizoma Coptidis metformin, low dose has the trend that reduces the mice carbohydrate tolerance.
(3), the Rhizoma Coptidis metformin causes the influence of the hypoglycemic activity of hyperglycemia mice to alloxan
100 of ICR mices, male, body weight 20 ± 2g.Wherein 10 as the normal control group, and water tail vein injection alloxan 60mg/Kg after 6 hours is can't help in remaining mice fasting, surveys blood glucose after four days, chooses the mice of blood glucose value more than 15mmol/L and is divided into 5 groups at random.Matched group and model group are irritated stomach equal-volume normal saline, and positive group gives diabetes pill 2.5g/kg, and other three groups give the Rhizoma Coptidis metformin shown in the table 3 large, medium and small three dosage respectively.Irritate stomach every day 1 time, 0.6ml/, successive administration was surveyed blood glucose after 30 days, the results are shown in Table 3.
Table 3 Rhizoma Coptidis metformin causes the influence of the hypoglycemic activity of hyperglycemia mice to alloxan
Compare *: p＜0.05, * *: P＜0.001 with model group.Compare with matched group: △ △ △ p＜0.001
Table 3 is the result show: administration one month, Rhizoma Coptidis metformin 4g crude drug/kg causes the hyperglycemia mouse blood sugar to alloxan tangible blood sugar reducing function.
(4), the Rhizoma Coptidis metformin causes the therapeutical effect of hyperglycemic rat to alloxan
100 of SD rats, male, reserve 10 rats as the normal control group, with equivalent normal saline tail vein injection, all the other rat tail vein injection alloxan 40mg/Kg inject back 5 days docking measuring blood sugar of blood extracting, select the rat of blood glucose value between 20-33mmol/l, carry out random packet, guarantee respectively to organize rat blood sugar value and body weight uniform balance.Press the administration respectively of the listed dosage of table 4, ten week backs are surveyed blood glucose, T-CHOL, triglyceride, HDL-C (HDL-C), fasting insulin, body weight (g), kidney coefficient (internal organs weight in wet base/body weight), amount of drinking water (ml) and cataract a situation arises and (are designated as 1 with an eye generation cataract, two eye generation cataract are designated as 2, no cataract is designated as 0), the results are shown in Table 4,5,6,7.
The influence of table 4 pair hyperglycemic rat body weight, kidney coefficient, amount of drinking water and cataract incidence rate
Compare *: p＜0.05 with model group.Compare △ △ △: p＜0.001 with matched group
Table 4 is the result show: in ten weeks of administration, the heavy dose of 3.2g crude drug/Kg of Rhizoma Coptidis metformin can significantly reduce the cataractous incidence rate of diabetes rat; Variation to body weight, amount of drinking water, kidney coefficient does not have significance, but the trend of improvement is arranged.
Table 5 Rhizoma Coptidis metformin causes the influence of hyperglycemic rat blood glucose to alloxan
Compare *: p＜0.05 with model group; *: p＜0.01.Compare △ △ △: p＜0.001 with matched group
Table 6 Rhizoma Coptidis metformin is to the influence of hyperglycemic rat triglyceride, fasting insulin
Compare * *: p＜0.05 with model group.Compare △ △ △: p＜0.001 with matched group
Table 7 Rhizoma Coptidis metformin is to the influence of hyperglycemic rat T-CHOL, high density lipoprotein
Compare *: p＜0.05 with model group.
Table 5,6,7 results show: in ten weeks of administration, Rhizoma Coptidis metformin 3.2g crude drug/kg causes hyperglycemic rat to alloxan tangible blood sugar reducing function; The blood fat rising that alloxan is caused hyperglycemic rat has the obvious suppression effect; T-CHOL there is the reduction effect, then not obvious to the influence of fasting insulin and high density lipoprotein.
(5), the Rhizoma Coptidis metformin is to the influence of diabetic mice swimming time
100 of ICR mices, male, body weight 20 ± 2g.Wherein 10 as the normal control group, and water tail vein injection alloxan 60mg/Kg after 6 hours is can't help in remaining mice fasting, surveys blood glucose after four days, chooses the mice of blood glucose value more than 15mmol/L and is divided into 6 groups at random, 10 every group.Matched group and model group are irritated stomach equal-volume normal saline, positive group gives Radix Ginseng decocting liquid 1g crude drug/kg, and other three groups give the Rhizoma Coptidis metformin shown in the table 8 large, medium and small three dosage respectively, irritate stomach every day 1 time, 0.6ml/ only, 30min after time administration does not put into bucket with mice, the about 30cm of the depth of water, 23 ℃ of water temperatures, 21 ℃ of room temperatures write down every Mus swimming time (putting into the time of bucket to mice whole body submerged from mice), surpass 3 hours press and calculate in 3 hours.The results are shown in Table 8.
Table 8 Rhizoma Coptidis metformin is to the influence of diabetic mice swimming time
Compare *: P＜0.05 with model group.
Table 8 is the result show: administration 30 days, Rhizoma Coptidis metformin 4.0g crude drug/kg causes the hyperglycemia mice to alloxan can obviously prolong swimming time.
(6), the Rhizoma Coptidis metformin is to the influence of diabetic mice macrophage phagocytic function
90 of ICR mices, male, body weight 20 ± 2g.Wherein 10 as the normal control group, and water tail vein injection alloxan 60mg/Kg after 6 hours is can't help in remaining mice fasting, surveys blood glucose after four days, chooses the mice of blood glucose value more than 15mmol/L and is divided into 6 groups at random, 10 every group.Matched group and model group are irritated stomach equal-volume normal saline, and positive group gives Radix Ginseng decocting liquid 1g crude drug/kg, and other three groups give the Rhizoma Coptidis metformin shown in the table 9 large, medium and small three dosage respectively, irritate stomach every day 1 time, and 0.6ml/ only.Every Mus lumbar injection chicken red blood cell (CRBC) 5% (V/V) after the administration, put to death after 4 hours, cut off abdominal cavity skin, the abdominal cavity injects normal saline 2ml, draw the abdominal cavity drop on slide after gently rubbing mouse web portion, put into the enamel tray that is lined with wet gauze, in 37 ℃ of incubation 30min, incubate completely, in normal saline, float CRBC and other cell do not engulfed, dry up, 1: 1 acetone-methanol solution is 5min fixedly, and 4%Giemsa-Wright dye liquor dyeing 3min dries the oily sem observation in back, count 100 macrophages, be calculated as follows phagocytic index.The results are shown in Table 9.
Table 9 Rhizoma Coptidis metformin is to the influence of diabetic mice macrophage phagocytic function
Compare *: P＜0.05 with model group; * *: P＜0.001.
Table 9 is the result show: administration 30 days, Rhizoma Coptidis metformin 4.0g crude drug/kg and 2.0g crude drug/kg cause the hyperglycemia mice to alloxan can obviously strengthen macrophage phagocytic function.
The many physical weakness of diabetes patient, consolidated statement 8, table 9 result show: the Rhizoma Coptidis metformin can also strengthen diabetes patient's body constitution.
(6), conclusion
Rhizoma Coptidis metformin 4g crude drug/kg has certain effect to improving the mice carbohydrate tolerance.Administration one month, Rhizoma Coptidis metformin 4g crude drug/kg causes the hyperglycemia mice to alloxan tangible blood sugar reducing function.In ten weeks of administration, Rhizoma Coptidis metformin 3.2g crude drug/Kg can significantly reduce the cataractous incidence rate of diabetes rat; Variation to body weight, amount of drinking water, kidney coefficient has the trend of improvement.Rhizoma Coptidis metformin 3.2g crude drug/kg causes hyperglycemic rat to alloxan tangible blood sugar reducing function; The blood fat rising that alloxan is caused hyperglycemic rat also has the obvious suppression effect; T-CHOL also there is the reduction effect.The Rhizoma Coptidis metformin does not have hypoglycemic activity to normal mouse.
The foregoing description is used for the present invention that explains, rather than limits the invention, and in the protection domain of spirit of the present invention and claim, any modification and change to the present invention makes all fall into protection scope of the present invention.
Claims (3)
1. a Chinese medicine for the treatment of diabetes is characterized in that, it is that 20～50% Rhizoma Coptidis, 20～50% Radix Ginseng Rubra, 10～20% Rhizoma Alismatis and 10～20% Radix Puerariae are made by percentage by weight.
2. the preparation method of Chinese medicine of the described treatment diabetes of claim 1 is characterized in that, may further comprise the steps:
(1) take by weighing material according to mass percent Rhizoma Coptidis 20～50%, Radix Ginseng Rubra 20～50%, Rhizoma Alismatis 10～20%, Radix Puerariae 10～20%.
(2) get Rhizoma Coptidis, add percent by volume and be 60～80% medicinal alcohol and reflux 1～3 time, each ethanol consumption is 7～9 times of medical material amount, each 0.5～1.5 hour; Collect alcohol reflux liquid, filter decompression recycling ethanol; Concentrated solution adds hydrochloric acid and transfers pH value to 2.0～3.0, standing over night, sucking filtration; Precipitate is added the hot water dissolving, filter, filtrate concentrates, the cooling standing over night, and sucking filtration, precipitate obtains Rhizoma Coptidis extract at 50～60 ℃ of following oven drying at low temperatures, and is standby;
(3) get Radix Ginseng Rubra, Rhizoma Alismatis, Radix Puerariae, extracting in water 1～3 time, each 0.5～1.5 hour, each 9～11 times of water gagings, merge each time water extract, filter, be concentrated into relative density 1.0～1.2, add ethanol and reach 60～80% to containing the alcohol amount, standing over night is filtered decompression filtrate recycling ethanol, medicine is concentrated into the concentrated solution of relative density 1.20～1.40 night, and is standby;
(4) get above-mentioned Rhizoma Coptidis extract and mix, get extractum with concentrated solution.
(5) get extractum, vacuum drying, dry thing is pulverized, sieve, the powder that gets dry extract adds mass percent and is lactose, 5%～7% sodium carboxymethyl cellulose, 10%～14% microcrystalline Cellulose and 0.6%～0.8% the medicinal magnesium stearate of dried cream powder quality 4%～6%, tabletting makes tablet.Or get extractum, and adding quality is the Icing Sugar of 1～2 times of amount of extractum quality and the mixture of dextrin, the weight ratio of Icing Sugar and dextrin is 1: 0.5～1 in the mixture, adopts the boiling granulating method to make granule, gets granule.Or get extractum, and vacuum drying, dry thing is pulverized, sieves, the powder that gets dry extract, adding percentage by weight is the starch mixing of dried cream powder quality 20%～25%, filled capsules makes capsule.
3. preparation method according to claim 2 is characterized in that, in the described step (5), described extractum is vacuum drying under 50～70 ℃, 600mm～800Hg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101624011A CN101406576B (en) | 2008-11-24 | 2008-11-24 | Chinese medicine for treating diabetes and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101624011A CN101406576B (en) | 2008-11-24 | 2008-11-24 | Chinese medicine for treating diabetes and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101406576A true CN101406576A (en) | 2009-04-15 |
| CN101406576B CN101406576B (en) | 2012-03-21 |
Family
ID=40569921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101624011A Expired - Fee Related CN101406576B (en) | 2008-11-24 | 2008-11-24 | Chinese medicine for treating diabetes and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101406576B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797312B (en) * | 2010-01-19 | 2011-11-16 | 南昌大学 | Method for preparing Alisma extract capable of inhibiting alpha-glucuroide activity |
| CN105025910A (en) * | 2013-01-10 | 2015-11-04 | 韩国韩医学研究院 | Pharmaceutical composition and functional food for prevention or treatment of diabetic complications or angioedema comprising natural extract |
-
2008
- 2008-11-24 CN CN2008101624011A patent/CN101406576B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797312B (en) * | 2010-01-19 | 2011-11-16 | 南昌大学 | Method for preparing Alisma extract capable of inhibiting alpha-glucuroide activity |
| CN105025910A (en) * | 2013-01-10 | 2015-11-04 | 韩国韩医学研究院 | Pharmaceutical composition and functional food for prevention or treatment of diabetic complications or angioedema comprising natural extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101406576B (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109549971A (en) | A kind of functional food and preparation method thereof adjusting hyperglycemia | |
| CN103405655A (en) | Traditional Chinese medicine composition for reducing blood glucose and preparation method thereof | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN101406576B (en) | Chinese medicine for treating diabetes and preparation method | |
| CN109223811B (en) | Ginsenoside composition with hypoglycemic activity | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN102266391A (en) | Composition extracted from medicinal and edible plants and able to adjust fasting and postprandial blood glucose simultaneously | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN106265717B (en) | Application of the dicliptera chinensis polysaccharide in preparing prevention diabetes medicament or health products | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN101406642B (en) | Antihypelipidemic compound formulation | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN103566227B (en) | A kind of Chinese medicine composition preventing and treating type 2 diabetes mellitus and preparation method thereof | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| CN102106993A (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN101293059B (en) | Compound Chinese medicine for treating diabetes | |
| CN107669860A (en) | A kind of Chinese medicine composition and its application with blood sugar reducing function | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103230552A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN104013928A (en) | Drug for treating hysteromyoma and endometriosis and preparation method thereof | |
| CN101791351B (en) | Glipizide-containing traditional Chinese and western medicine composition | |
| CN101791350B (en) | Glibenclamide-containing traditional Chinese and western medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120321 Termination date: 20171124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |